Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed
Permanent URI for this communityhttps://hdl.handle.net/20.500.14719/1741
Browse
25 results
Search Results
Publication Open Access The history of urinary stones: In parallel with civilization(Hindawi Publishing Corporation 410 Park Avenue, 15th Floor, 287 pmb New York NY 10022, 2013) Tefekli, Ahmet Hamdi; Cezayirli, Fatin; Tefekli, Ahmet Hamdi, Bahçeşehir Üniversitesi, Istanbul, Turkey; Cezayirli, Fatin, VKV Amerikan Hastanesi, Istanbul, TurkeyThe roots of modern science and history of urinary stone disease go back to the Ancient Egyptians and Mesopotamia. Hippocrates defined the symptoms of bladder stones. The first recorded details of perineal lithotomy were those of Cornelius Celsus. Ancient Arabic medicine was based mainly on classical Greco-Roman works. Interestingly, the Fourth Lateran Council in 1215 forbade physicians from performing surgical procedures, as contact with blood or body fluids was viewed as contaminating to men. With Renaissance new procedures could be tried on criminals. The first recorded suprapubic lithotomy was carried out by Pierre Franco in 1561. In 1874, Bigelow developed a lithotrite, which was introduced into the bladder under anaesthesia (called as litholopaxy). Young was the first to report ureteroscopy (1929). With advances in intracorporeal lithotripsy techniques, ureteroscopy became the treatment of choice for ureteric stones. In 1976, Fernstrom and Johannson established percutaneous access to remove a renal stone. However, with the introduction of the first extracorporeal shock wave machine in 1980, a dramatic change in stone management was observed. Civilization in parallel with scientific developments has brought us to a point where we try not to cut our patients for stone disease, as Hippocrates admonishes, but rather manage them with minimal invasive alternatives. © 2013 Ahmet Tefekli and Fatin Cezayirli. © 2014 Elsevier B.V., All rights reserved.Publication Metadata only AT1 antagonists: A patent review (2008 - 2012)(2013) Mavromoustakos, Thomas M.; Agelis, George; Durdagi, Serdar; Mavromoustakos, Thomas M., Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece; Agelis, George, Department of Chemistry, University of Patras, Rio, Greece, Eldrug S.A., Patra, Greece; Durdagi, Serdar, Department of Biophysics, Bahçeşehir Üniversitesi, Istanbul, TurkeyIntroduction: For two decades a class of pharmaceutical molecules with proved beneficial therapeutic properties, especially in hypertension, has been introduced in the market aiming to specifically prevent the detrimental effects of the peptide hormone Angiotensin II at the AT1 receptor. The prototype of this class was losartan and based on its structure, several drugs were launched and also called 'Sartans'. New structural features on these molecules can provide multi-target properties in the RAS or other systems. New methodologies were developed for the treatment of hypertension utilizing either AT1 antagonists alone or as cocktails. Areas covered: In this review article, authors aim to cover information provided by patents of the years 2008-2012. The rationale of writing this review article is to cover the most important patents which can forward the field with new important discoveries. Expert opinion: From the patent investigation it is clear that new areas on the subject are still offered for new discoveries. New structural features can be still considered in the synthetic compounds that can advance the knowledge and beneficial effects on diseases related to Angiotensin II and AT1 receptor. There is era also for new formulations (i.e., cyclodextrins, polymers and liposomes). The multitarget approach can be further strengthened and more combinations can be sought in the rational drug design for seeking cocktails. Furthermore, the revealing of the complexity of the RAS offers new avenues for novel targets and this must not be overlooked. © 2013 Informa UK, Ltd. © 2013 Elsevier B.V., All rights reserved.Publication Open Access Biological approaches to treating intervertebral disk degeneration: Devising stem cell therapies(Cognizant Communication Corporation [email protected] 3 Hartsdale Road Elmsford NY 10523-3701, 2015) Han, Inbo; Ropper, Alexander Eli; Konya, Deniz; Kabataş, Serdar; Toktaş, Zafer Orkun; Aljuboori, Zaid S.; Zeng, Xiang; Chi, John H.; Zafonte, Ross D.; Teng, Yang D.; Han, Inbo, Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States, Department of Neurosurgery, College of Medicine, Pochon CHA University, Pocheon, South Korea; Ropper, Alexander Eli, Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, United States; Konya, Deniz, Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey; Kabatas, Serdar, Department of Neurosurgery, Reyap Hospital, Tekirdag, Turkey; Toktaş, Zafer Orkun, Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey; Aljuboori, Zaid S., Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States, University of Louisville School of Medicine, Louisville, United States; Zeng, Xiang, Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States, Department of Neurosurgery, College of Medicine, Pochon CHA University, Pocheon, South Korea; Chi, John H., Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States; Zafonte, Ross D., Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital Network, Boston, United States; Teng, Yang D., Department of Neurosurgery, Brigham and Women's Hospital, Boston, United States, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital Network, Boston, United States, Division of SCI Research, VA Medical Center, United StatesIntervertebral disk (IVD) degeneration is a common, chronic, and complex degeneration process that frequently leads to back pain and disability, resulting in a major public health issue. In this review we describe biological therapies under preclinical or clinical development with an emphasis on stem cell-based multimodal approaches that target prevention and treatment of IVD degeneration. Systematical review of the basic science and clinical literature was performed to summarize the current status of devising biological approaches to treating IVD degeneration. Since the exact mechanisms underlying IVD degeneration have not yet been fully elucidated and conservative managements appear to be mostly ineffective, current surgical treatment focuses on removal of the pathological disk tissues combined with spinal fusion. The treatment options, however, often produce insufficient efficacy and even serious complications. Therefore, there have been growing demands and endeavors for developing novel regenerative biology-guided strategies for repairing the IVD via delivery of exogenous growth factors, introduction of therapeutic genes, and transplantation of stem cells, or combinatorial therapies. Overall, the data suggest that when applied under a recovery neurobiology principle, multimodal regimens comprising ex vivo engineered stem cell-based disks hold a high potential promise for efficacious clinical translations. © 2017 Elsevier B.V., All rights reserved.Publication Open Access Interferometric reflectance imaging sensor (IRIS)—a platform technology for multiplexed diagnostics and digital detection(MDPI AG Postfach Basel CH-4005, 2015) Avcı, Oğuzhan; Lortlar Ünlü, Neşe; Yalçın Ozkumur, Ayça; Ünlü, M. Selim; Avci, Oğuzhan, Boston University College of Engineering, Boston, United States; Lortlar Ünlü, Nese, Boston University College of Engineering, Boston, United States, Department of Electrical and Electronic Engineering, Bahçeşehir Üniversitesi, Istanbul, Turkey; Yalcin Ozkumur, Ayca, Department of Electrical and Electronic Engineering, Bahçeşehir Üniversitesi, Istanbul, Turkey; Ünlü, M. Selim Selim, Boston University College of Engineering, Boston, United States, Boston University College of Engineering, Boston, United StatesOver the last decade, the growing need in disease diagnostics has stimulated rapid development of new technologies with unprecedented capabilities. Recent emerging infectious diseases and epidemics have revealed the shortcomings of existing diagnostics tools, and the necessity for further improvements. Optical biosensors can lay the foundations for future generation diagnostics by providing means to detect biomarkers in a highly sensitive, specific, quantitative and multiplexed fashion. Here, we review an optical sensing technology, Interferometric Reflectance Imaging Sensor (IRIS), and the relevant features of this multifunctional platform for quantitative, label-free and dynamic detection. We discuss two distinct modalities for IRIS: (i) low-magnification (ensemble biomolecular mass measurements) and (ii) high-magnification (digital detection of individual nanoparticles) along with their applications, including label-free detection of multiplexed protein chips, measurement of single nucleotide polymorphism, quantification of transcription factor DNA binding, and high sensitivity digital sensing and characterization of nanoparticles and viruses. © 2018 Elsevier B.V., All rights reserved.Publication Metadata only Incidence and severity of retinopathy of prematurity in Turkey(BMJ Publishing Group [email protected], 2015) Bas, Ahmet Yagmur; Koç, Esin Merve; Dílmen, Uǧur; Oĝuz, Şerife Suna; Ovalı, Hüsnü Fahri; Demirel, Nihal; Zenciroǧlu, Ayşeg̈ul; Tekin, Neslihan; Caner, Ibrahim; Arslanoǧlu, Sertaç; Bas, Ahmet Yagmur, Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Kecioren, Turkey; Koç, Esin Merve, Department of Neonatology, Gazi Üniversitesi, Ankara, Turkey; Dílmen, Uǧur, Department of Neonatology, Dr. Zekai Tahir Burak Women's Hospital, Ankara, Turkey; Oĝuz, Şerife Suna, Department of Neonatology, Dr. Zekai Tahir Burak Women's Hospital, Ankara, Turkey; Ovalı, Hüsnü Fahri, Zeynep Kamil Maternity and Children's Training and Research Hospital, Istanbul, Turkey; Demirel, Nihal, Department of Neonatology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Kecioren, Turkey; Zenciroǧlu, Ayşeg̈ul, Dr. Sami Ulus Maternity and Children's Hospital, Ankara, Turkey; Tekin, Neslihan, Eskişehir Osmangazi Üniversitesi, Eskisehir, Turkey; Caner, Ibrahim, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Arslanoǧlu, Sertaç, Dr. Behcet Uz Children's Hospital, Izmir, TurkeyBackground: The purpose of this study was to estimate the current incidence of retinopathy of prematurity (ROP) and the need for treatment in preterm infants in Turkey. Methods: The study included preterm infants who had been screened for ROP between 2011 and 2013 in 49 neonatal intensive care units. Infants with birth weight (BW) ≤1500 g or ≤32 weeks' gestational age and those with BW >1500 g or >32 weeks' GA with an unstable clinical course were included. The incidence of any ROP or severe ROP and treatment modalities were determined. Results: The study population included 15 745 preterm infants: 11 803 (75%) with GA ≤32 weeks, and 3942 (25%) with GA >32 weeks. Overall, 30% were found to have any stage of ROP, and 5% had severe ROP. Severe ROP was diagnosed in 8.2% of infants with BW ≤1500 g and 0.6% of infants with BW >1500 g. Of all infants diagnosed with ROP, 16.5% needed laser photocoagulation, and 20 patients born at >32 weeks' GA required this treatment modality. Vitroretinal surgery was performed in 28 infants with severe ROP: 23 with GA ≤28 weeks and 5 with GA 29-32 weeks. Conclusions: The findings of our study have the important implication that more mature babies are at risk of severe ROP requiring treatment. An effective programme for detecting and treating ROP should be established in Turkey. © 2019 Elsevier B.V., All rights reserved.Publication Open Access Best method for analysis of brain oscillations in healthy subjects and neuropsychiatric diseases(Elsevier B.V., 2016) BaÅŸar, Erol; Gölbaşı, Bilge Turp; Tülay, Elif Elif; Aydın, Serap; Başar-Eroǧlu, Canan; BaÅŸar, Erol, Cognition and Complex Systems Research Center, T.C. Istanbul Kültür Üniversitesi, Istanbul, Turkey; Gölbaşı, Bilge Turp, Cognition and Complex Systems Research Center, T.C. Istanbul Kültür Üniversitesi, Istanbul, Turkey; Tülay, Elif Elif, Cognition and Complex Systems Research Center, T.C. Istanbul Kültür Üniversitesi, Istanbul, Turkey; Aydın, Serap, Department of Biomedical Engineering, Bahçeşehir Üniversitesi, Istanbul, Turkey; Başar-Eroǧlu, Canan, Universität Bremen, Bremen, GermanyThe research related to brain oscillations and their connectivity is in a new take-off trend including the applications in neuropsychiatric diseases. What is the best strategy to learn about functional correlation of oscillations? In this report, we emphasize combined application of several analytical methods as power spectra, adaptive filtering of Event Related Potentials, inter-trial coherence and spatial coherence. These combined analysis procedure gives the most profound approach to understanding of EEG responses. Examples from healthy subjects, Alzheimer's Diseases, schizophrenia, and Bipolar Disorder are described. © 2017 Elsevier B.V., All rights reserved.Publication Open Access Visualization of airway(Klinicka Bolnica Sestre Milosrdnice, 2016) Toker, Kamíl; Toker, Kamíl, Department of Anesthesiology, Bahçeşehir Üniversitesi, Istanbul, TurkeyThe author provides an overview of the history of optical instruments for airway management in anesthesiology. It systematically demonstrates the development of laryngoscope down to the present time when video laryngoscope has been introduced in clinical practice. © 2017 Elsevier B.V., All rights reserved.Publication Open Access The Risk of Atrial Fibrillation With Ivabradine Treatment: A Meta-analysis With Trial Sequential Analysis of More Than 40000 Patients(John Wiley and Sons Inc. [email protected], 2016) Tanboga, İbrahim Halil; Topçu, Selim; Aksakal, Enbiya; Gulcu, Oktay; Aksakal, Emrah; Aksu, Uǧur; Oduncu, Vecih; Ulusoy, Fatih Rıfat; Sevimli, Serdar; Kaymaz, Cihangir; Tanboga, İbrahim Halil, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey, Department of Biostatistics, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Topçu, Selim, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey, Department of Biostatistics, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Aksakal, Enbiya, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Gulcu, Oktay, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Aksakal, Emrah, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Aksu, Uǧur, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Oduncu, Vecih, Bahçeşehir Üniversitesi, Istanbul, Turkey; Ulusoy, Fatih Rıfat, Department of Cardiology, Yalova Devlet Hastanesi, Yalova, Turkey; Sevimli, Serdar, Department of Cardiology, Ataturk University, Faculty of Medicine, Erzurum, Turkey; Kaymaz, Cihangir, Department of Cardiology, Kosuyolu Heart Center, Istanbul, TurkeyRecent trials reported that risk of atrial fibrillation (AF) is increased in patients using ivabradine compared with controls. We performed this meta-analysis to investigate the risk of AF association with ivabradine treatment on the basis of data obtained from randomized controlled trials (RCTs). We searched PubMed, EMBASE, Scopus, and the Cochrane Library for RCTs that comprised >100 patients. The incidence of AF was assessed. We obtained data from European Medicines Agency (EMA) scientific reports for the RCTs in which the incidence of AF was not reported. We used trial sequential analysis (TSA) to provide information on when we had reached firm evidence of new AF based on a 15% relative risk increase (RRI) in ivabradine treatment. Three RCTs and 1 EMA overall oral safety set (OOSS) pooled analysis (included 5 RCTs) were included in the meta-analysis (N = 40 437). The incidence of AF was 5.34% in patients using ivabradine and 4.56% in placebo. There was significantly higher incidence of AF (24% RRI) in the ivabradine group when compared with placebo before (RR: 1.24, 95% confidence interval: 1.08-1.42, P = 0.003, I 1980 = 53%) and after excluding OOSS (RR: 1.24, 95% confidence interval: 1.06-1.44, P = 0.008). In the TSA, the cumulative z-curve crossed both the traditional boundary (P = 0.05) and the trial sequential monitoring boundary, indicating firm evidence for ≥15% increase in ivabradine treatment when compared with placebo. Study results indicate that AF is more common in the ivabradine group (24% RRI) than in controls. © 2017 Elsevier B.V., All rights reserved.Publication Metadata only A comparison of off- and on-pump beating-heart coronary artery bypass surgery on long-term cardiovascular events(Clinics Cardive Publishing (PTY)Ltd PO Box 1013, Durbanville, 7551, 2017) Gürbüz, Orçun; Kumtepe, Gencehan; Yolgösteren, Atif; Özkan, Hakan; Karal, Ilker Hasan; Ercan, Abdulkadir; Ener, Serdar; Gürbüz, Orçun, Department of Cardiovascular Surgery, Balikesir Üniversitesi, Balikesir, Turkey; Kumtepe, Gencehan, Department of Cardiovascular Surgery, Balikesir Üniversitesi, Balikesir, Turkey; Yolgösteren, Atif, Department of Cardiovascular Surgery, Bursa Uludağ Üniversitesi, Bursa, Turkey; Özkan, Hakan, Bahçeşehir Üniversitesi, Istanbul, Turkey; Karal, Ilker Hasan, Department of Cardiovascular Surgery, Samsun Education and Research Hospital, Samsun, Turkey; Ercan, Abdulkadir, Department of Cardiovascular Surgery, Balikesir Üniversitesi, Balikesir, Turkey; Ener, Serdar, Department of Cardiovascular Surgery, Doruk Hospital, Bursa, TurkeyObjective: Our aim was to compare short-term outcomes and long-term major adverse cardiovascular event (MACE)-free survival and independent predictors of long-term MACE after off-pump (OPCAB) versus on-pump beating-heart (ONBHCAB) coronary artery bypass grafting (CABG). Methods: We retrospectively reviewed data of all consecutive patients who underwent elective CABG, performed by the same surgeon, from January 2003 to October 2009. A propensity score analysis was carried out to adjust for baseline characteristics and a total of 398 patients were included: ONBHCAB (n = 181), OPCAB (n = 217). Results: OPCAB was associated with significantly shorter ventilation times (p ≤ 0.001), intensive care unit stay (p ≤ 0.001) and hospital stay (p ≤ 0.001). The total blood loss was significantly more in the ONBHCAB group (p ≤ 0.001), and accordingly, the number of transfused blood units was significantly lower in the OPCAB group (p ≤ 0.001). Incidence of peri-operative renal complications were significantly higher in the ONBHCAB group (p = 0.004). The OPCAB group showed significantly lower long-term MACE-free survival (p = 0.029). The mean number of transfused blood units was the only independent predictor of MACE (HR: 1.218, 95% CI: 1.0891.361, p = 0.001). Conclusion: OPCAB provided better long-term MACE-free survival compared with ONBHCAB. Fewer units of blood transfused following OPCAB surgery may have been the main reason for this result. © 2017 Elsevier B.V., All rights reserved.Publication Metadata only Surgery for Benign Gynecological Disorders Improve Endometrium Receptivity: A Systematic Review of the Literature(SAGE Publications Inc. [email protected], 2017) Çelik, Önder; Acet, Mustafa; Küçük, Tansu; Haberal, Esra Tuştaş; Acet, Tuba; Bozkurt, Murat; Şahin, Levent; Verit, Fatma Ferda; Çalişkan, Eray; Çelik, Önder, Department of Obstetrics and Gynecology, Private Clinic, Usak, Turkey; Acet, Mustafa, Department of Obstetrics and Gynecology, İstanbul Medipol Üniversitesi, Istanbul, Turkey; Küçük, Tansu, Department of Obstetrics and Gynecology, Acıbadem Mehmet Ali Aydınlar Üniversitesi, Istanbul, Turkey; Haberal, Esra Tuştaş, Department of Obstetrics and Gynecology, Umraniye Education and Research Hospital, Istanbul, Turkey; Acet, Tuba, Department of Obstetrics and Gynecology, Medicine Hospital, Istanbul, Turkey; Bozkurt, Murat, Department of Obstetrics and Gynecology, Sakarya Üniversitesi, Serdivan, Turkey; Şahin, Levent, Department of Obstetrics and Gynecology, Kafkas Üniversitesi, Kars, Turkey; Verit, Fatma Ferda, Department of Obstetrics and Gynecology, Suleymaniye Maternity Education and Research Hospital, Istanbul, Turkey; Çalişkan, Eray, Department of Obstetrics and Gynecology, Bahçeşehir Üniversitesi, Istanbul, TurkeyRegardless of the anatomical locations, some benign gynecological disorders (BGDs) such as peritoneal endometriosis, ovarian endometrioma, adenomyosis, uterine leiomyomas, endometrial polyps, uterine septum, and hydrosalpinges may lead to implantation failure. Despite progress in medical therapies, surgery remains a mainstay of BGDs treatment. Although our knowledge of endometrial receptivity after BGDs surgery is limited, it has allowed for significant improvement in the treatment of female subfertility. Many researchers studied on pregnancy outcome following BGDs surgery, but they did not investigate the possible impact of surgery on endometrial receptivity. They, therefore, concluded that pregnancy rates improved after BGDs surgery based on clinical observations. Many of these clinicians believe that surgical resection of BGDs leads to removal of local mechanical effect over the endometrium. Moreover, they accept that BGDs surgery may inhibit the detrimental signaling and secretion of some molecules from the BGDSs into the endometrium that may lead to favorable effect on the endometrium. However, so far, data from randomized controlled trials or systematic review or meta-analyses to answer the question whether surgical treatment of BGDs can improve endometrial receptivity are lacking. The purpose of this systematic review was to evaluate the results of available publications dealing with the impact of reproductive surgery for BGDs on endometrial receptivity. © 2017 Elsevier B.V., All rights reserved.
- «
- 1 (current)
- 2
- 3
- »